Since the KRAS mutant rectal adenocarcinomas were significantly more represented in the CAIXhigh group uniformly for both NAT and UT samples, we also performed a combined analysis using the exact CAIX scores related to the KRAS status in the unified rectal carcinoma cohort (n = 89, mutant n = 46, and wild type n = 43). The gene discussed is BRD2; the disease is rectum adenocarcinoma.